Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15  months of galcanezumab treatment

CONCLUSIONS: Galcanezumab 300 mg monthly had a favorable tolerability and safety profile in patients with chronic CH with up to 15 months of treatment.PMID:34806783 | DOI:10.1111/head.14234

Source: Headache - November 22, 2021 Category: Neurology Authors: Miguel J A L áinez Jean Schoenen Chad Stroud Jennifer Bardos Mark Bangs Phebe Kemmer Richard Wenzel Dulanji K Kuruppu James Michael Martinez Tina M Oakes Source Type: research